Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Nivolumab & Colorectal Cancer (CRC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)), Nivolumab is approved by both FDA and EMA for metastatic/unresectable Colorectal Cancer (CRC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)). The FDA granted accelerated approval to nivolumab for adult patients with MSI‑H/dMMR metastatic CRC whose disease has progressed following treatment with a fluoropyrimidine, oxaliplatin a…